摘要
Viruses often manipulate ubiquitination pathways to facilitate their replication and pathogenesis.CUL2ZYG11B known as the substrate receptor of cullin-2 RING E3 ligase,is bound by SARS-CoV-2 ORF10 to increase its E3 ligase activity,leading to degradation of IFT46,a protein component of the intraflagellar transport(IFT)complex B.This results in dysfunctional cilia,which explains certain symptoms that are specific to COVID-19.However,the precise molecular mechanism of how ORF10 recognizes CUL2ZYG11B remains unknown.Here,we determined the crystal structure of CUL2ZYG11B complexed with the N-terminal extension(NTE)of SARS-CoV-2 ORF10(2.9 A°).The structure reveals that the ORF10 N-terminal heptapeptide(NTH)mimics the Gly/N-degron to bind CUL2ZYG11B.Mutagenesis studies identified key residues within ORF10 that are key players in its interaction with CUL2ZYG11B both in ITC assay and in vivo cells.In addition,we prove that enhancement of CUL2ZYG11B activity for IFT46 degradation by which ORF10-mediated correlates with the binding affinity between ORF10 and CUL2ZYG11B.Finally,we used a Global Protein Stability system to show that the NTH of ORF10 mimics the Gly/N-degron motif,thereby binding competitively to CUL2ZYG11B and inhibiting the degradation of target substrates bearing the Gly/N-degron motif.Overall,this study sheds light on how SARS-CoV-2 ORF10 exploits the ubiquitination machinery for proteasomal degradation,and offers valuable insights for optimizing PROTAC-based drug design based on NTH CUL2ZYG11B interaction,while pinpointing a promising target for the development of treatments for COVID-19.
基金
the following staff members and grant support.BL19U1 beamline of the National Facility for Protein Science in Shanghai(NFPS),BL17U1 beamline,and BL10U2 beamline at the Shanghai Synchrotron Radiation Facility.We thank the staff of PX III beamline at the Swiss Light Source,PaulScherrer Institute(Villigen Switzerland)for assistance in data collection.We thank the staffs from the Core Facility of National Institute of Pathogen Biology,Chinese Academy of Medical Sciences.This work was supported by National Key Research and Development Program of China(2023YFC2307803)
Chinese Academy of Medical Sciences(CAMS)Innovation Fund for Medical Sciences(2022-I2M-1-021,China)
the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(2023-PT310-04,China)
National Natural Science Foundation of China(82341095
82261160398
82072291
82272308)
the Fundamental Research Funds for the Central Universities(3332021092,China).